Tag James C. Yang

Tumor Immunology and Immunotherapy

Cancer immunotherapy has had a long and generally disappointing clinical history, until recently. There were clues from early landmark clinical trials using high-dose interleukin-2 (IL-2), which effected dramatic and durable complete responses in small subsets of patients with metastatic melanoma…